A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The aim of this phase 2 study is to evaluate the safety and efficacy of single dose IV
infusion of BRII-196 and BRII-198 given as combination therapy in patients with severe
COVID-19, and mild to moderate COVID-19 and asymptomatic carrier.